Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.
Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...
MedPage Today on MSN
Hemolysis a Growing Concern With Newer Sapien TAVR Device
Could hemolytic anemia be related to the new sealing skirt on the valve?
Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...
Pulsed-field ablation, transcatheter heart valves, and IVL are among the top stories, as they drive growth among the largest ...
A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from ...
Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results